<DOC>
	<DOCNO>NCT01627340</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety Engerix™-B ( hepatitis B vaccine ) administer primary vaccination course 0 , 1 6 month adult without type 2 diabetes mellitus .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Engerix™-B Adults With Without Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects , opinion investigator , comply requirement protocol . A male female subject age 20 year time screen . Written inform consent obtain subject screening . Subjects diagnose type 2 diabetes document within past five year , accord criterion specify American Diabetes Association currently take form antidiabetic intervention document investigator ; control subject diagnosis documented history diabetes , HbA1c le 6.5 % , determine laboratory screening test . Normal renal function define estimate glomerular filtration rate ( GFR ) ≥ 50 mL/min , estimate Modification Diet Renal Disease ( MDRD ) Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation , determine laboratory screening test . Seronegative hepatitis B surface antigen ( HBsAg ) , antiHBs antibody antibody hepatitis B core antigen ( anti HBc ) , determine laboratory screening test . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day screen Visit 1 , agree continue adequate contraception entire treatment period two month completion vaccination series . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration longacting immunemodifying drug within 6 month study entry plan administration time study period . Administration vaccine foreseen study protocol start 30 day dose vaccine end 30 day dose , exception inactivate influenza vaccine allow time study administer separate site . Concurrently participate another clinical study , time study period , subject expose investigational protocolspecified noninvestigational product . Any previous complete incomplete vaccination hepatitis B since birth . Any confirm suspected immunosuppressive immunodeficient condition , include HIV infection , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine , include latex . Advanced heart failure severe clinical condition significantly reduce subject 's life expectancy . Acute disease and/or fever time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Any history alcohol drug abuse past 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>adult</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Engerix™-B</keyword>
</DOC>